Regulatory Focus™ > News Articles > J&J Earnings Drag as Regulatory Problems Accumulate

J&J Earnings Drag as Regulatory Problems Accumulate

Posted 18 April 2012 | By Alexander Gaffney, RAC 

Life sciences giant Johnson & Johnson (J&J) managed to increase first quarter profits by 12.5% despite a decrease in revenue of 0.2%, the company said in a statement.

But the company's profits were sorely depressed by a series of regulatory issues, including recalls, shortages and legal battles, reports The Associated Press.

Among J&J's many issues during Q1:

J&J's problems don't seem to be abating, either. Australian and New Zealand regulators announced 16 April they were recalling the company's MITCH TRH hip components manufactured by subsidiary Finsbury Orthapedics unit. The same product was recalled by UK regulators earlier in April as well.

Bloomberg noted the company is revising profit forecasts for the year upward as increased demand for new medicines were exceeding expectations, easing some of that pressure on the company.

Read more:

Yahoo! Finance - J&J 1Q profit jumps 12.5 pct. despite sales dip

Med City News - Johnson & Johnson's Q1 performance paints a mixed picture

Forbes - Johnson & Johnson's Q1 Malady: Manufacturing, Drug Shortage Push U.S. Sales Down 5.1%

Bloomberg - J&J Raises Forecast as Profit Climbs on Demand for Drugs

Regulatory Focus - J&J Faces Larger Fine as DOJ Rejects $1B Risperdal Settlement

Regulatory Focus - Arkansas Slams J&J With $1.2 Billion Fine for Risperdal Marketing Tactics

Regulatory Focus - NYTimes: J&J Privately Jettisoned Hip Implant Line After FDA Raised Questions

Regulatory Focus - Bloomberg: J&J Sold Unapproved Medical Device for Years Prior to Approval

Regulatory Focus - After String of Quality Issues, J&J CEO Weldon Retires to $143M

Biopharm International - EMA Addresses Ben Venue Quality Issues

New York Times - Popular J.&J. Drugs May Not Return Until 2013

Fierce Medical Devices - Australia, New Zealand, recall J&J hip implant components

Philly Pharma - J&J: McNeil Problems Continue, Increasing Costs

The Pink Sheet - J&J Says Penalties In Arkansas Risperdal Case 'Excessive,' Seeks New Trial

Regulatory Focus newsletters

All the biggest regulatory news and happenings.